Hypertrophic Cardiomyopathy Therapeutics Market Size in the 7MM was ~USD 646 million in 2023, is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover which therapies are expected to grab the Hypertrophic Cardiomyopathy Market Share @ Hypertrophic Cardiomyopathy Market Outlook- https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hypertrophic Cardiomyopathy Market Report
• In May 2025, Bristol-Myers Squibb announced a study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
• In May 2025, Novartis Pharmaceuticals conducted a study was to determine if LCZ696 can improve functional capacity (via improved peak VO2) in non-obstructive hypertrophic cardiomyopathy (HCM) patient population over the course of 50 weeks of treatment.
• In May 2025, Tenaya Therapeutics organized a study will consist of 2 escalating dose cohorts (groups). The study will enroll at least 6 and as many as 30 patients. All patients will receive active drug (TN-201 Gene Therapy). The study will follow patients for 5 years following a single dose of TN-201.
• In the assessment done by DelveInsight, the estimated total Hypertrophic Cardiomyopathy Prevalent Cases in the 7MM were ~1,079 thousand in 2023.
• The highest tHypertrophic Cardiomyopathy diagnosed prevalent cases were accounted for by the US in 2023 (~118 thousand), which is expected to show a rise in the future.
• Among the European countries, Germany had the highest Hypertrophic Cardiomyopathy Diagnosed Prevalent Cases with ~32 thousand cases, followed by France, which had diagnosed prevalent population of ~25 thousand in 2023. On the other hand, Spain had the lowest diagnosed prevalent population (~19 thousand cases).
• Japan had ~4 thousand total diagnosed prevalent cases of Hypertrophic Cardiomyopathy in 2023, accounting for approximately 2% in 7MM.
• In 2023, in the US, the gender-specific diagnosed prevalent cases of Hypertrophic Cardiomyopathy were highest for males (~57%), as compared to females (~43%), which is attributed to factors such as hormonal differences and physiology, lifestyle and occupational factors and others.
• In the UK, among type-specific cases of hypertrophic cardiomyopathy in 2023, the highest number of cases was of Obstructive hypertrophic cardiomyopathy, with ~16,000 cases, while Non-obstructive hypertrophic cardiomyopathy had the least, with ~8,000 cases.
• The increase in Hypertrophic Cardiomyopathy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Hypertrophic Cardiomyopathy Market is anticipated to witness growth at a considerable CAGR.
• The leading Hypertrophic Cardiomyopathy Companies such as La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
• Promising Hypertrophic Cardiomyopathy Therapies such as Mavacamten, EDG-7500, LCZ696, Trientine, TN-201, Ranolazine, Sotagliflozin and others.

Stay ahead in the Hypertrophic Cardiomyopathy Therapeutics Market with DelveInsight's Strategic Report @ Hypertrophic Cardiomyopathy Market Outlook- https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypertrophic Cardiomyopathy Epidemiology Segmentation in the 7MM
The epidemiology section of Hypertrophic Cardiomyopathy offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Hypertrophic Cardiomyopathy Prevalent Cases
• Hypertrophic Cardiomyopathy Diagnosed Prevalent Cases
• Hypertrophic Cardiomyopathy Gender-specific Diagnosed Prevalent Cases
• Hypertrophic Cardiomyopathy Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Hypertrophic Cardiomyopathy Epidemiology trends @ Hypertrophic Cardiomyopathy Prevalence- https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Hypertrophic Cardiomyopathy Drugs
• Mavacamten: Bristol Myers Squibb
Mavacamten is an investigational, novel, oral, allosteric modulator of cardiac myosin; mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation, resulting in hypercontractility, left ventricular hypertrophy, and reduced compliance. In Hypertrophic Cardiomyopathy Clinical and preclinical studies, mavacamten has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility, and increased diastolic compliance. MyoKardia is developing mavacamten to treat conditions in which excessive cardiac contractility and impaired diastolic filling of the heart are the underlying cause.

Emerging Hypertrophic Cardiomyopathy Drugs
• Aficamten (CK-274): Cytokinetics
Aficamten, or CK-274, is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations for the potential treatment of hypertrophic cardiomyopathies (hypertrophic cardiomyopathy). CK-274 was designed to reduce the hypercontractility associated with hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy causes the heart to thicken and stiffen, eventually limiting its ability to pump blood. CK-274 addresses this hypercontractility by blocking some myosins from pulling, resulting in less contraction or fewer hands on the rope. In preclinical models, CK-274 reversed and reduced thickening and stiffening of the heart.

• MYK-224: Bristol Myers Squibb
MYK-224 is a small molecule drug that is being developed by MyoKardia, a subsidiary of Bristol-Myers Squibb, to treat diastolic heart failure (HFpEF) and obstructive hypertrophic cardiomyopathy. It is taken orally and targets the heart's cardiac myosin motor protein to normalize filling and contractility.

To learn more about Hypertrophic Cardiomyopathy treatment guidelines, visit @ Hypertrophic Cardiomyopathy Treatment Market Landscape- https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypertrophic Cardiomyopathy Market Outlook
Cardiomyopathy is a term that refers to abnormalities of heart muscle contractility, covering a heterogeneous range of etiologies. Hypertrophic cardiomyopathy is characterized by left ventricular hypertrophy and hypercontractility. It is almost always caused by mutations of genes encoding sarcomeric proteins. Current pharmacological treatment strategies of Hypertrophic cardiomyopathy are mainly centered on managing the symptoms and minimizing disease progression. However, it is important to keep in mind that these strategies are not disease-specific since they target the neurohormonal system and excitation-contraction coupling (ECC) while the basic disease mechanism remains untreated. Nevertheless, pharmacological therapy plays an essential role in restoring quality of life (QoL) and reducing the risk of disease-related complications..

Hypertrophic Cardiomyopathy Drugs Uptake
The drug chapter of the Hypertrophic Cardiomyopathy report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Hypertrophic Cardiomyopathy.

Major Hypertrophic Cardiomyopathy Companies
La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.

Learn more about the FDA-approved drugs for Hypertrophic Cardiomyopathy @ Drugs for Hypertrophic Cardiomyopathy Treatment- https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hypertrophic Cardiomyopathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Hypertrophic Cardiomyopathy Companies- La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporation, BioMarck Pharmaceuticals, and others.
• Hypertrophic Cardiomyopathy Therapies- Mavacamten, EDG-7500, LCZ696, Trientine, TN-201, Ranolazine, Sotagliflozin and others.
• Hypertrophic Cardiomyopathy Market Dynamics: Hypertrophic Cardiomyopathy Market Drivers and Barriers
• Hypertrophic Cardiomyopathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Hypertrophic Cardiomyopathy Drugs in development @ Hypertrophic Cardiomyopathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hypertrophic-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Hypertrophic Cardiomyopathy Report Introduction
3. Hypertrophic Cardiomyopathy Market Overview at a Glance
4. Executive Summary of Hypertrophic Cardiomyopathy
5. Key Events
6. Hypertrophic Cardiomyopathy Epidemiology and Market Methodology
7. Hypertrophic Cardiomyopathy Disease Background and Overview
8. Hypertrophic Cardiomyopathy Epidemiology and Patient Population
9. Patient Journey
10. Hypertrophic Cardiomyopathy Marketed Therapies
11. Hypertrophic Cardiomyopathy Emerging Therapies
12. Hypertrophic Cardiomyopathy: Market Analysis
13. Hypertrophic Cardiomyopathy KOL Views
14. Hypertrophic Cardiomyopathy SWOT Analysis
15. Hypertrophic Cardiomyopathy Unmet Needs
16. Hypertrophic Cardiomyopathy Market Access
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.